Clinical Remission of Severe Crohn’s Disease with Empagliflozin Monotherapy in a Pediatric Patient with Glycogen Storage Disease Type 1b-Reference-Cited by-同舟云学术

Clinical Remission of Severe Crohn’s Disease with Empagliflozin Monotherapy in a Pediatric Patient with Glycogen Storage Disease Type 1b

Published:2023-08-28 Issue:4 Volume:4 Page:e356
ISSN:2691-171X
Container-title:JPGN Reports
language:en
Short-container-title:

Author:

Collen Lauren V.¹,Newburger Peter E.²³,Snapper Scott B.¹

Affiliation:

1. Division of Gastroenterology, Hepatology, and Nutrition, Boston Children’s Hospital, Harvard Medical School, Boston, MA

2. Departments of Pediatrics and Molecular, Cell, and Cancer Biology, UMass Chan Medical School, Worcester, MA

3. Dana-Farber/Boston Children’s Hospital Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA.

Abstract

Glycogen storage disease type 1b (GSD1b) is associated with inflammatory bowel disease and congenital neutropenia. Neutropenia in GSD1b is caused by the accumulation of 1,5-anhydroglucitol-6-phosphate. Empagliflozin is an antidiabetic drug that promotes renal excretion of this metabolite. We report on a patient with refractory GSD1b-associated inflammatory bowel disease who is in clinical remission on empagliflozin monotherapy.

Publisher

Wiley

Subject

General Earth and Planetary Sciences,General Environmental Science

Reference14 articles.

1. Inflammatory bowel disease-like colitis in glycogen storage disease type 1b.;Yamaguchi;Inflamm Bowel Dis,2001

2. Glycogen storage disease type I: diagnosis, management, clinical course and outcome. results of the European Study on Glycogen Storage Disease Type I (ESGSD I).;Rake;Eur J Pediatr,2002

3. Granulocyte colony-stimulating factor in glycogen storage disease type 1b. Results of the European Study on Glycogen Storage Disease Type 1.;Visser;Eur J Pediatr,2002

4. Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency.;Veiga-da-Cunha;Proc Natl Acad Sci U S A,2019

5. Brief report: treatment of chronic inflammatory bowel disease in glycogen storage disease type Ib with colony-stimulating factors.;Roe;N Engl J Med,1992

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neutrophil functions in patients with neutropenia due to glycogen storage disease type 1b treated with empagliflozin;Blood Advances;2024-05-31

2. Treatment recommendations for glycogen storage disease type IB- associated neutropenia and neutrophil dysfunction with empagliflozin: Consensus from an international workshop;Molecular Genetics and Metabolism;2024-03

3. Catalyzing change: Implementing standardised reporting in monogenic inflammatory bowel disease research;Journal of Pediatric Gastroenterology and Nutrition;2024-02-14

4. DBS are suitable for 1,5-anhydroglucitol monitoring in GSD1b and G6PC3-deficient patients taking SGLT2 inhibitors to treat neutropenia;Molecular Genetics and Metabolism;2023-11